In the field of oncology, HER2-targeted therapies have functioned like “biological missiles,” bringing hope to countless patients. However, the emergence of drug resistance, like a difficult-to-break “curse,” has become the biggest obstacle in clinical treatment. To address this challenge, Kyinno Biotechnology has successfully constructed and validated the globally rare Enhertu-resistant H2030 lung cancer cell line and in vivo models, providing a powerful new tool to overcome resistance.
I. Glory and Challenges: A Brief History of HER2-Targeted Therapy
HER2 (Human Epidermal Growth Factor Receptor 2) is a critical oncogenic driver and was first identified in breast cancer. Its overexpression or mutation continuously stimulates tumor cell growth, proliferation, and metastasis. The evolution of HER2-targeted therapy has progressed from monoclonal antibodies (trastuzumab, pertuzumab), to small-molecule TKIs (lapatinib, neratinib), and now to revolutionary antibody-drug conjugates (ADCs). Each advancement has significantly improved therapeutic efficacy, yet drug resistance has remained a persistent challenge.
Molecular strategies of HER2-targeted therapy (doi.org/10.3390/cancers15010183)
II. The Anti-Cancer “Superstar”: The Rise of Enhertu (DS-8201)
Enhertu (generic name: trastuzumab deruxtecan) is a standout representative of next-generation ADC therapeutics, composed of three key components:
Targeting engine: a humanized anti-HER2 monoclonal antibody that precisely recognizes and binds to HER2 on tumor cell surfaces.
Highly potent “payload”: the topoisomerase I inhibitor deruxtecan (DXd), with cytotoxic potency thousands of times greater than traditional chemotherapeutics.
Smart “linker”: a cleavable tetrapeptide linker that is selectively cleaved by intracellular enzymes, enabling precise payload release within tumor cells.
With its “bystander effect” (ability to kill neighboring HER2-low or HER2-negative cells), Enhertu has fundamentally reshaped the treatment landscape for HER2-positive and HER2-low cancers, establishing itself as a true game-changer.
III. The Escalating Arms Race: Mechanisms of Enhertu Resistance
Despite its remarkable efficacy, resistance to Enhertu is inevitable. The underlying mechanisms are complex and include:
Target-related alterations: downregulation or mutation of HER2, reducing ADC binding efficiency.
Activation of downstream signaling pathways: such as PI3K/AKT/mTOR or RAS/MAPK pathways, bypassing HER2 inhibition.
Abnormal ADC processing: defects in endocytosis, lysosomal dysfunction, or reduced linker cleavage efficiency, preventing effective payload release.
Payload resistance: tumor cells develop resistance to DXd, similar to resistance seen with conventional chemotherapeutics.
Tumor microenvironment changes: including heterogeneity and fibrosis, which hinder drug delivery.
Potential mechanisms of resistance to anti-HER2 ADCs (doi: 10.3390/cancers14010154)
Therefore, constructing preclinical models that faithfully recapitulate clinical resistance is foundational for developing next-generation therapeutic strategies.
IV. Precision Engineering: Methodology for Constructing Enhertu-Resistant H2030 In Vivo Models and In Vitro Resistant Cells
To accurately replicate the clinical evolution of resistance, we employed the gold-standard strategy of in vivo induction.
Model selection: NCI-H2030 (NSCLC cell line) was used to establish mouse subcutaneous xenograft models. This model is initially sensitive to Enhertu, making it ideal for resistance induction.
Dosing regimen: tumor-bearing mice were treated with cyclic in vivo administration of Enhertu. In the initial phase, tumors showed significant regression.
Resistance induction: treatment was not halted upon tumor shrinkage; instead, continuous selective pressure was applied. After multiple cycles of challenge and selection, a small population of surviving tumor cells resumed proliferation, ultimately forming resistant tumor strains capable of sustained growth under effective dosing.
Model expansion and preservation: resistant tumor tissues were serially passaged in mice to stably expand this valuable resistant model repository.
Primary culture and preservation of resistant cells: resistant tumor tissues were dissociated into single cells, followed by primary in vitro culture and clonal selection to establish monoclonal cell lines.
Construction of Enhertu-resistant H2030 in vivo model (Kyinno Biotechnology)
V. Data-Driven Validation: Rigorous Characterization of the Resistant Model
Kyinno Biotechnology confirmed the successful construction and robustness of this model through in vivo pharmacodynamic data:
In vivo efficacy validation:
Parental cell line KC-0371 NCI-H2030 CDX model: Enhertu, 10 mpk IV single dose, significantly inhibited tumor growth, with TGI ~94%.
Resistant tumor tissue model NCI-H2030/Enhertu-R: Enhertu, 10 mpk IV single dose, showed no significant tumor growth inhibition, with Day 14 TGI only 18%, demonstrating a clear resistant phenotype.
Resistant cell-derived KC-6031 NCI-H2030/Enhertu-R CDX model: Enhertu, 10 mpk IV single dose, showed no significant tumor growth inhibition, with Day 18 TGI of 30%, also demonstrating a clear resistant phenotype.
Efficacy of Enhertu in the NCI-H2030/Enhertu-R resistant model
In vitro efficacy validation:
KC-0631 NCI-H2030-EnhertuR exhibited significant resistance to common ADC payloads such as DXd, SN38, and Exatecan, while showing slightly increased sensitivity to MMAE.
In vitro validation of NCI-H2030-EnhertuR cell line
VI. Empowering Drug Development: Your Ideal Partner for Resistance Research
This Enhertu-resistant H2030 in vivo and in vitro model provides an excellent platform for evaluating strategies to overcome drug resistance, including:
Combination therapy studies: testing whether combining Enhertu with agents of different mechanisms (such as TKIs, immunotherapies, MEK inhibitors) can reverse resistance.
Next-generation ADC evaluation: assessing the activity of next-generation ADCs targeting the same or different antigens in this resistant model.
Deep exploration of resistance mechanisms: supporting biomarker discovery and precision medicine development.
Beyond this, Kyinno Biotechnology has extensive experience and platforms for tumor model development. If you are investigating resistance models for other targets (such as KRAS, EGFR, c-MET, TROP2) or other therapeutics (RMC6236, various payloads), feel free to reach out. We provide customized model construction and pharmacological evaluation solutions.
Break the resistance barrier starting here. Contact our scientific team and work with Kyinno Biotechnology to explore the next breakthrough in cancer therapy.
